摘要
目的探讨糖类抗原CA19-9、CA50及CEA联合检测对胰腺癌患者的临床诊断价值。方法用放射免疫分析法检测胰腺癌病人75例、良性胰腺疾病69例、正常对照组71例的CA19-9、CA50及CEA血清水平。结果胰腺癌患者血清CA19-9、CA50及CEA值均明显高于正常组及良性胰腺疾病组,两者比较有显著性差异(P<0.05或P<0.01);CA19-9、CA50及CEA联合检测较单测任何一项其灵敏度、特异度均有提高,分别达到86.7%和87.9%。结论胰腺癌肿瘤标志物CA19-9、CA50及CEA可作为早期诊断胰腺癌的工具,联检CA19-9、CA50及CEA能提高对胰腺癌的诊断和鉴别诊断率。
Objective To investigate the clinical value of combined test of serum CA19-9, CA50 and CEA levels in the diagnosis of patients with pancreatic cancer. Methods Serum levels of CA19-9, CA50 and CEA in 75 cases of pancreatic cancer,69 cases of benign pancreatic lesions and 71 normal controls were detected by radioimmunoassay. Results Serum CA19-9 ,CA50 and CEA levels in pancreatic cancer patients were significantly higher than those in normal controls and benign pancreatic lesions patients（P 〈0.05 or P 〈0.01 ）. If serum CA19-9 ,CA50 and CEA were detected simultaneously,the sensitivity and specificity of diagnosis of pancreatic cancer could be improved, reached 86.7% and 87.9% respectively. Conclusion The changes of serum CA19-9, CA50 and CEA level are helpful to diagnose pancreatic cancer. Serum CA19-9, CA50 and CEA detected simultaneously could improve the sensitivity and specificity in diagonosis and differential diagnosis of pancreatic cancer.
出处
《咸宁学院学报（医学版）》
2007年第2期119-121,共3页
Journal of Xianning Univarsity(medical Sciences)
